LBT Announces Retirement Of CEO
12 October 2015, Adelaide: The Board of Australian medical technology company LBT Innovations Limited (ASX: LBT) has announced that its long-standing Chief Executive Officer, Lusia Guthrie, will retire from the company as CEO in 2016 due to health reasons.
Mrs Guthrie has been CEO of the Adelaide-based technology developer since she co-founded the company in 2004. She steered LBT through its formative years, negotiating the global licensing of its first technology, the MicroStreak® automated culture plate streaking system (in market as PREVI® Isola), and more recently, the development of its promising plate analysis technology, APAS® (the Automated Plate Assessment System).
LBT’s Chairman, Bob Finder, said that the company and the Board would miss Mrs Guthrie’s pivotal leadership, but that it understood her reasons for stepping down.
“This is a sad day for LBT, as we are losing our leader just as the company is about to realise the fruits of some of her greatest labours,” said Mr Finder. “However, we do understand why Lusia has to leave and we fully support her.
“LBT would never have been formed without Lusia, who together with Scientific Director John Glasson was the driving force in commercialising MicroStreak, which enabled us to list on the ASX. She is leaving us in extremely good shape based on the recent licensing revenue for MicroStreak and the excellent clinical trial results of APAS.”
Lusia will continue to support and advise the company through the transition to the new CEO and potentially beyond.
“The past 11 years have been demanding and challenging, but at the same time they have been some of the most rewarding years of my professional career. The team we have assembled are some of the brightest and most inspiring people I have worked with. The LBT Board has been extremely supportive in giving us the leeway and resources to pursue our ideas and vision. To say that I have been proud to lead this team would be a serious understatement.”
Mr Finder said that the company is now in the process of recruiting a new CEO, while Lusia continues with her full duties and authority in company matters.
About LBT Innovations
LBT Innovations (LBT) is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company has two breakthrough products in microbiology automation: MicroStreak®, which provides automation of culture plate streaking, and APAS®, a breakthrough in automated culture plate reading, interpretation and reporting. Based on LBT’s innovative intelligent image interpretative platform, APAS specifically addresses the automated imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a joint venture with Hettich AG Switzerland to drive the commercialisation of APAS products.
LBT also has a third product in development, WoundVue™, a proposed automation solution to assist in the management of chronic wounds.
For more information, see www.lbtinnovations.com
Help employers find you! Check out all the jobs and post your resume.
Mrs Guthrie has been CEO of the Adelaide-based technology developer since she co-founded the company in 2004. She steered LBT through its formative years, negotiating the global licensing of its first technology, the MicroStreak® automated culture plate streaking system (in market as PREVI® Isola), and more recently, the development of its promising plate analysis technology, APAS® (the Automated Plate Assessment System).
LBT’s Chairman, Bob Finder, said that the company and the Board would miss Mrs Guthrie’s pivotal leadership, but that it understood her reasons for stepping down.
“This is a sad day for LBT, as we are losing our leader just as the company is about to realise the fruits of some of her greatest labours,” said Mr Finder. “However, we do understand why Lusia has to leave and we fully support her.
“LBT would never have been formed without Lusia, who together with Scientific Director John Glasson was the driving force in commercialising MicroStreak, which enabled us to list on the ASX. She is leaving us in extremely good shape based on the recent licensing revenue for MicroStreak and the excellent clinical trial results of APAS.”
Lusia will continue to support and advise the company through the transition to the new CEO and potentially beyond.
“The past 11 years have been demanding and challenging, but at the same time they have been some of the most rewarding years of my professional career. The team we have assembled are some of the brightest and most inspiring people I have worked with. The LBT Board has been extremely supportive in giving us the leeway and resources to pursue our ideas and vision. To say that I have been proud to lead this team would be a serious understatement.”
Mr Finder said that the company is now in the process of recruiting a new CEO, while Lusia continues with her full duties and authority in company matters.
About LBT Innovations
LBT Innovations (LBT) is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company has two breakthrough products in microbiology automation: MicroStreak®, which provides automation of culture plate streaking, and APAS®, a breakthrough in automated culture plate reading, interpretation and reporting. Based on LBT’s innovative intelligent image interpretative platform, APAS specifically addresses the automated imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a joint venture with Hettich AG Switzerland to drive the commercialisation of APAS products.
LBT also has a third product in development, WoundVue™, a proposed automation solution to assist in the management of chronic wounds.
For more information, see www.lbtinnovations.com
Help employers find you! Check out all the jobs and post your resume.